Paul R A, Rudramurthy S M, Meis J F, Mouton J W, Chakrabarti A
Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
Antimicrob Agents Chemother. 2015 Oct;59(10):6615-9. doi: 10.1128/AAC.00637-15. Epub 2015 Jul 27.
This study aimed to explore any mutation in the CYP51 gene conferring azole resistance in Aspergillus flavus. Two voriconazole-resistant and 45 voriconazole-susceptible isolates were included in the study. Sequence analysis demonstrated a T1025C nucleotide change in CYP51C, resulting in the Y319H amino acid substitution in one resistant isolate. However, the earlier described T788G mutation in CYP51C conferring voriconazole resistance in A. flavus isolates was present in all isolates, irrespective of their susceptibility status.
Antimicrob Agents Chemother. 2015-10
Antimicrob Agents Chemother. 2012-2-6
Antimicrob Agents Chemother. 2018-10-24
J Mycol Med. 2020-3-26
Pol J Microbiol. 2024-6-1
Mycoses. 2025-4
J Antimicrob Chemother. 2025-3-14
Front Microbiol. 2023-11-14
Microbiol Spectr. 2023-8-17
G3 (Bethesda). 2022-11-4
Front Microbiol. 2022-5-31
PLoS Comput Biol. 2014-4-10
Antimicrob Agents Chemother. 2012-2-6
J Antimicrob Chemother. 2011-10-25